ArticleHistopathology2018
Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial.
Article in Histopathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Does Lymph Node Dissection During Esophagectomy Impact the Long-Term Prognosis for Complete Responders After Neoadjuvant Therapy? A Meta-analysis.Annals of surgical oncology · 2026Pooled it
- Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2022Pooled it
- Predicting lymph node metastases with endoscopic resection in cT2N0M0 oesophageal cancer: A systematic review and meta-analysis.United European gastroenterology journal · 2020Pooled it
- Meta-analysis of the influence of a positive circumferential resection margin in oesophageal cancer.BJS open · 2019Pooled it
- Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2020Trial
- Refining post-neoadjuvant risk stratification in ESCC with lymph node regression grade.Frontiers in oncology · 2026Article
- ASO Author Reflections: Tumor Location and TRG in Neoadjuvant Immunotherapy for Esophageal Cancer.Annals of surgical oncology · 2025Article
- Chemotherapy Response as a Predictor of Survival in Post-neoadjuvant Esophagectomy Specimens.Cureus · 2025Article
- Characterizing Patients with ypT0N1 Gastric Adenocarcinoma Within the AJCC Staging System.Annals of surgical oncology · 2025Article
- German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus-version 4.0.ESMO gastrointestinal oncology · 2025Review
- Article
- Equivalent prognosis with no lymph node metastasis to pathological complete remission in patients with localized advanced esophageal cancer after neoadjuvant triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by curative surgery: a single-center retrospective cohort study.Journal of thoracic disease · 2024Article
- Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma.British journal of cancer · 2024Review
- Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials.British journal of cancer · 2023Article
- Combined regression score predicts outcome after neoadjuvant treatment of oesophageal cancer.British journal of cancer · 2023Article
- Outcome and prognostic factors in patients undergoing salvage therapy for recurrent esophagogastric cancer after multimodal treatment.Journal of cancer research and clinical oncology · 2023Article
- Automated detection and delineation of lymph nodes in haematoxylin & eosin stained digitised slides.Journal of pathology informatics · 2023Article
- Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy.Frontiers in oncology · 2023Article
- Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil.World journal of clinical oncology · 2021Article
- Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsNeoadjuvant chemotherapy (NAC) remains an important therapeutic option for advanced oesophageal cancer (OC). Pathological tumour regression grade (TRG) may offer additional information by directing adjuvant treatment and/or follow-up but its clinical value remains unclear. We analysed the prognostic value of TRG and associated pathological factors in OC patients enrolled in the Medical Research Council (MRC) OE02 trial. METHODS AND
resultsHistopathology was reviewed in 497 resections from OE02 trial participants randomised to surgery (S group; n = 244) or NAC followed by surgery [chemotherapy plus surgery (CS) group; n = 253]. The association between TRG groups [responders (TRG1-3) versus non-responders (TRG4-5)], pathological lymph node (LN) status and overall survival (OS) was analysed. One hundred and ninety-five of 253 (77%) CS patients were classified as 'non-responders', with a significantly higher mortality risk compared to responders [hazard ratio (HR) = 1.53, 95% confidence interval (CI) = 1.05-2.24, P = 0.026]. OS was significantly better in patients without LN metastases irrespective of TRG [non-responders HR = 1.87, 95% CI = 1.33-2.63, P < 0.001 versus responders HR = 2.21, 95% CI = 1.11-4.10, P = 0.024]. In multivariate analyses, LN status was the only independent factor predictive of OS in CS patients (HR = 1.93, 95% CI = 1.42-2.62, P < 0.001). Exploratory subgroup analyses excluding radiotherapy-exposed patients (n = 48) showed similar prognostic outcomes.
conclusionLymph node status post-NAC is the most important prognostic factor in patients with resectable oesophageal cancer, irrespective of TRG. Potential clinical implications, e.g. adjuvant treatment or intensified follow-up, reinforce the importance of LN dissection for staging and prognostication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.